Research Article

In Silico Studies of a Novel Scaffold of Acetylsalicylic Acid Derivatives Against EGFR by Molecular Docking and Molecular Dynamics Simulations

Volume: 45 Number: 2 June 30, 2024
EN

In Silico Studies of a Novel Scaffold of Acetylsalicylic Acid Derivatives Against EGFR by Molecular Docking and Molecular Dynamics Simulations

Abstract

In this study, a molecular docking study was performed to propose the acetylsalicylic acid derivative 2-[(4-Acetylphenyl)carbamoyl]phenyl acetate (AMPBS) as a potential cancer candidate targeting the Epidermal Growth Factor Receptor (EGFR). The native ligand erlotinib was used as a control compound. The calculated docking score of -7.4 kcal/mol compared to the native ligand erlotinib of -7.0 kcal/mol of AMPBS compound revealed a promising anticancer activity. The stability of the complex was interpreted by careful analysis of the root mean square deviation (RMSD), root mean square fluctuations (RMSF) and mean hydrogen bond number (Hb) plots obtained from the MD trajectories. The ADMET properties of AMPBS were evaluated using relevant online tools. Drug-likeness studies showed that AMPBS is suitable for use in living organisms. It was predicted that AMPBS in the active pocket could be a promising inhibitor due to its high binding energy, interaction mechanism and retention in the active pocket.

Keywords

Thanks

I would like to acknowledge the support provided by the project Grant No: 2013FBE013 at Pamukkale University.

References

  1. [1] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D., Global cancer statistics, CA Cancer J. Clin., 61 (2) (2011) 69-90.
  2. [2] Shang D., Sun D., Shi C., Xu J., Shen M., Hu X., Liu H., Tu Z., Activation of epidermal growth factor receptor signaling mediates cellular senescence induced by certain pro‐inflammatory cytokines, Aging Cell, 19 (5) (2020) e13145.
  3. [3] Ukirde R., Sawant R., Nerkar A., Role of Epidermal Growth Factor Receptor Inhibitors in Treating Cancer, Curr Trends Pharm Pharm Chem, 2 (1) (2020) 57-63.
  4. [4] Stamos J., Sliwkowski M.X., Eigenbrot C., Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor, J. Biol. Chem., 277 (48) (2002) 46265-46272.
  5. [5] Cordover E., Minden A., Lehman S., Zhao O., Signaling pathways downstream to receptor tyrosine kinases: Targets for cancer treatment, J. Cancer Metastatis Treat., 2020 (2020) 1-19.
  6. [6] Raymond E., Faivre S., Armand J.P., Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy, Drugs, 60 (2000) 15-23.
  7. [7] Ahmad, A. A., Hussain, K., Shah, M. R., Ashhad Halimi, S. M., Rabbi, F., Ahmad, Z., Khan, I., Rauf, A., Alshammari, A., Rasul Suleria, H. A. (2023). Molecular Insights into the In Vivo Analgesic and Anti-Inflammatory Activity of Indomethacin Analogues, ACS Omega, 8(33), 30048-30056.
  8. [8] Das A.J., Das M.K., Singh S.P., Saikia P.P., Singh N., Islam J., Ansari A., Chattopadhyay P., Rajamani P., Miyaji T., Synthesis of salicylic acid phenylethyl ester (SAPE) and its implication in immunomodulatory and anticancer roles, Sci. Rep., 12(1) (2022) 8735.

Details

Primary Language

English

Subjects

Pharmaceutical Chemistry , Atomic and Molecular Physics

Journal Section

Research Article

Publication Date

June 30, 2024

Submission Date

December 26, 2023

Acceptance Date

June 6, 2024

Published in Issue

Year 2024 Volume: 45 Number: 2

APA
Bayrakdar, A. (2024). In Silico Studies of a Novel Scaffold of Acetylsalicylic Acid Derivatives Against EGFR by Molecular Docking and Molecular Dynamics Simulations. Cumhuriyet Science Journal, 45(2), 274-281. https://doi.org/10.17776/csj.1410033

Cited By

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December